What is Adagene?
Adagene Inc. operates at the intersection of advanced immunology and oncology, focusing on the discovery and production of next-generation monoclonal antibody therapies. The company distinguishes itself through a unique platform-driven approach, which enables the rapid identification and optimization of therapeutic candidates designed to overcome traditional limitations in cancer treatment. By maintaining a rigorous focus on clinical-stage development, Adagene has established a formidable presence in the biotechnology landscape, effectively bridging the gap between laboratory innovation and patient-centric medical solutions. Its market position is further bolstered by a strategic commitment to high-impact research, ensuring that its therapeutic portfolio remains at the forefront of modern oncology.
How much funding has Adagene raised?
Adagene has raised a total of $320M across 6 funding rounds:
Series A
$8M
Series B
$28M
Series C
$50M
Series D
$69M
Stock Offering
$140M
Other Financing Round
$25M
Series A (2014): $8M with participation from Fidelity Asia Growth, WuXi Venture Fund, and Fidelity Biosciences
Series B (2016): $28M led by Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), GP Healthcare Capital, F-Prime Capital (formerly Fidelity Biosciences), New World TMT, and WuXi Corporate Venture Fund
Series C (2018): $50M supported by AVIC Trust, Gopher Asset Management, Sequoia China, New World TMT, and King Star Capital
Series D (2020): $69M featuring General Atlantic
Stock Issuance/Offering (2021): $140M, investors not publicly disclosed
Other Financing Round (2025): $25M with participation from Sanofi
Key Investors in Adagene
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care.
Sequoia China
Sequoia Capital in China manages funds focused on venture, growth, and late-stage opportunities, acting as an active, value-added partner to entrepreneurs and management teams to create global market leaders.
General Atlantic
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in sectors such as healthcare, life sciences, and technology to accelerate international expansion.
What's next for Adagene?
With the successful completion of this major strategic investment, Adagene is well-positioned to advance its clinical trials and enhance its research infrastructure. The company's forward-looking strategy emphasizes the maturation of its lead assets and the potential for international partnerships to broaden the reach of its antibody technologies. Investors and industry observers anticipate that this capital will facilitate the scaling of manufacturing capabilities and the pursuit of regulatory milestones, which are essential for long-term commercial viability. As Adagene continues to navigate the complexities of the global biotech market, its focus remains on delivering transformative outcomes for patients while maximizing value through sustained scientific excellence and operational discipline.
See full Adagene company page
